Patients with advanced ovarian cancer and a BRCA mutation achieve disease-free intervals of about 5 years thanks to treatment with PARP inhibitors Published on 06/05/2021 PARP inhibitors are a series of drugs that intervene in the repair of genetic damage, and it has been shown that, after surgery or chemotherapy, they achieve high remission rates in advanced ovarian cancer with disease-free survival rate of up to 56 months compared to the 13 months previously achieved.